HepTcell is a Subunit Vaccine owned by Altimmune, and is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing.

FP-02 is a T-cell vaccine containing Densigens that target different conserved viral or tumour associated proteins such that each Densigen is fused to a fluorocarbon tail. Following T-cell vaccination, patients infected with the corresponding virus or patients harbouring the corresponding tumour, rapidly produce large numbers of both antigen-specific CD4 and CD8 T-cells. CD8 T-cells then kill virus-infected cells or tumour cells directly while CD4 T-cells can, in addition to promoting direct cell killing, recruit other branches of the immune system, including antibodies to attack the target cells.

The revenue for HepTcell is expected to reach a total of $1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the HepTcell NPV Report.

HepTcell was originated by Immune Targeting Systems and is currently owned by Altimmune.

HepTcell Overview

FP-02 (Hepsyn-B, HepTcell) is under development for the treatment of chronic hepatitis-B virus infections. It is administered through intramuscular route. FP-02 is a depovaccine product that contains eight Densigens which are derived from highly conserved regions of the Hepatitis B virus. It is developed based on Densigen platform.

Altimmune Overview

Altimmune, is a a biopharmaceutical company. It focuses on developing liver disease and immune modulating therapies. The company’s pipeline products include ALT-801, a glucagon receptor to treat metabolic dysfunction that leads to non-alcoholic steatohepatitis (NASH). Altimmune also offers nasovax, an intranasally administered recombinant influenza vaccine; and heptcell, an immunotherapy to patients chronically infected with the hepatitis B virus; nasoshield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores. In addition, its products find its application in the treatment of acute respiratory infections, chronic viral infections, and cancer. Altimmune is headquartered in Gaithersburg, Maryland, the US.

The company reported revenues of (US Dollars) US$4.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 46.1% over FY2020. The operating loss of the company was US$96.9 million in FY2021, compared to an operating loss of US$54.8 million in FY2020. The net loss of the company was US$97.1 million in FY2021, compared to a net loss of US$49 million in FY2020.

Quick View – HepTcell

Report Segments
  • Innovator
Drug Name
  • HepTcell
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Companies
  • Sponsor Company: Altimmune
  • Originator: Immune Targeting Systems
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.